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Abstract
Background—Immunoglobulin E (IgE) is both a marker and mediator of allergic inflammation.
Despite reported differences in serum total IgE levels by race-ethnicity, African American and
Latino individuals have not been well represented in genetic studies of total IgE.
Objective—To identify the genetic predictors of serum total IgE levels.
Methods—We used genome wide association (GWA) data from 4,292 individuals (2,469
African Americans, 1,564 European Americans, and 259 Latinos) in the EVE Asthma Genetics
Consortium. Tests for association were performed within each cohort by race-ethnic group (i.e.,
African American, Latino, and European American) and asthma status. The resulting p-values
were meta-analyzed accounting for sample size and direction of effect. Top single nucleotide
polymorphism (SNP) associations from the meta-analysis were reassessed in six additional cohorts
comprising 5,767 individuals.
Results—We identified 10 unique regions where the combined association statistic was
associated with total serum IgE levels (P-value <5.0×10−6) and the minor allele frequency was
≥5% in two or more population groups. Variant rs9469220, corresponding to HLA-DQB1, was the
most significantly associated SNP with serum total IgE levels when assessed in both the
replication cohorts and the discovery and replication sets combined (P-value = 0.007 and
2.45×10−7, respectively). In addition, findings from earlier GWA studies were also validated in
the current meta-analysis.
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Conclusion—This meta-analysis independently identified a variant near HLA-DQB1 as a
predictor of total serum IgE in multiple race-ethnic groups. This study also extends and confirms
the findings of earlier GWA analyses in African American and Latino individuals.
Keywords
meta-analysis; genome wide association study; total immunoglobulin E; race-ethnicity; continental
population groups
INTRODUCTION
Immunoglobulin E (IgE) is an important mediator in allergic inflammation and is often
elevated in individuals with atopic conditions, such as asthma.(1–3) Recently published
genome wide association studies (GWAS) for asthma and serum total IgE levels suggest that
there are some, but not many, overlapping top-hit single nucleotide polymorphisms (SNPs)
in genes associated with these phenotypes.(4–6) The independence (i.e., lack of genetic
pleiotropy) of these two phenotypes is also supported by minimal shared variance between
the heritable components of serum total IgE and airway responsiveness.(7) In addition,
although environmental exposures influence total IgE levels, studies in twins suggest that
genetic inheritance accounts for the majority of variation in levels between individuals.(8;9)
Serum total IgE levels differ by population group in the U.S. with higher levels reported in
both African American and Latino individuals when compared with non-Hispanic white
individuals (henceforward referred to as European Americans).(10–13) As genetic ancestry
has been shown to be associated with total IgE levels, it is possible that these population-
level differences have some genetic underpinnings.(14) This is also supported by
heterogeneity in linkage signals for total IgE among these three population groups.(15)
However, despite these potential differences, African American and Latino individuals have
not been well represented in genetic studies of total IgE to date.
The EVE consortium comprises nine research groups across the U.S. with genome wide
genotype data on individuals with and without asthma. The assembled study participants are
broadly representative of three major population groups (i.e., African American, European
American, and Latino individuals) in North America and have data on asthma-associated
phenotypes, including serum total IgE. We describe here the results of a meta-analysis of
GWAS for serum total IgE, combining results from the various EVE investigators.
Associations were first determined among subgroups of individuals defined by asthma status
and self-identified race-ethnicity before combining so as to minimize the potential
confounding effects of these characteristics.
METHODS
Study populations
The EVE consortium comprises nine investigative teams throughout the U.S., each with
genome wide association data for asthma from case-control, trio, or extended family
studies.(16) All of the cohorts represented in the meta-analysis (i.e., the discovery set) were
part of the EVE consortium, and each of these individual study populations has been
described in detail previously.(17–25) These study populations are broadly representative of
the major North American population groups and were recruited through clinics and health
systems in the U.S., Puerto Rico, Mexico, and Barbados. All studies included in the current
analysis were approved by their respective institutional review boards.
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Only the EVE samples in which the participants had serum total IgE measured at the time of
screening or enrollment were included in the current meta-analysis. These included the
following studies: the Study of Asthma Phenotypes and Pharmacogenomic Interactions by
Race-ethnicity (SAPPHIRE), the Genetic Research on Asthma in the African Diaspora
(GRAAD), Genetics of Asthma in Latino Americans (GALA), the Childhood Asthma
Management Program (CAMP), the Childhood Asthma Research and Education Network
(CARE), the Chicago Asthma Genetics Study (CAG), the National Heart, Lung, and Blood
Institute (NHLBI) Collaborative Studies of the Genetics of Asthma (CSGA), and the Severe
Asthma Research Program (SARP). The latter three studies make up the NHLBI-supported
SNP Typing for Association with Multiple Phenotypes from Existing Epidemiologic Data
(STAMPEED) consortium (heretofore collectively referred to by that acronym).
SAPPHIRE is an ongoing prospective cohort study to determine the genetic determinants of
inhaled corticosteroid response.(17;18) Participants were aged 12–56 years, had a physician
diagnosis of asthma, demonstrated bronchodilator reversibility (>12% increase in forced
expiratory volume at one second [FEV1]), and had no prior diagnosis (in the electronic
medical record or by patient report) of chronic obstructive pulmonary disease (COPD) or
congestive heart failure (CHF). All patients were recruited from a single, large health system
covering southeast Michigan. A subset of these individuals was genotyped using the
Affymetrix 6.0 GeneChip Array (Affymetrix, Inc., Santa Clara, California). Controls for
SAPPHIRE were from the Wayne County Health Environment Allergy and Asthma
Longitudinal Study, and included expectant women age ≥21 years from the Detroit
metropolitan area and receiving care from the same health system. This group was
genotyped using the Affymetrix 5.0 GeneChip Array or the 500K Mapping Array.
The GRAAD-AA study comprised African American individuals with asthma (self-
reported) and non-asthmatic control patients from the Baltimore-Washington D.C. area.(19)
The GRAAD-AC study consisted of extended families from Barbados with at least one
asthma proband.(19) In this study, a diagnosis of asthma required a self-reported history,
physician diagnosis, and a history of wheezing without an upper respiratory infection.
Individuals were genotypied on the Illumina HumanHap650Y versions 1 and 3 BeadChips
(Illumina, Inc., San Diego, California).
GALA is a trio study including asthma probands age 8–40 years with a physician diagnosis
of mild to moderate-severe asthma and symptoms at least twice in the two years preceding
enrollment.(20) Individuals were recruited from sites in San Francisco, New York City,
Puerto Rico, and Mexico City. Individuals were genotyped on the Affymetrix 6.0 GeneChip
Array.
The CAMP subjects were part of a multi-center clinical trial of children with mild to
moderate asthma and airway responsiveness by methacholine challenge (≥20% drop in
FEV1 with ≤12.5 mg/dl of methacholine).(23) While parents of these children were also
recruited for this trio study, only the children with total IgE data were included in the current
analysis. Individuals were genotyped on the Illumina HumanHap500 version 3 BeadChip.
CARE represents a series clinical trials, 5 of which contributed to the current meta-analysis
(PEAK,(26) PACT,(27) CLIC,(28) AIMS,(29) and MARS(30)). All participants were children
with physician diagnosed asthma. Parents of these subjects were also recruited to compose a
trio study, but the only the children for whom we had total IgE data were included in this
analysis. Individuals were genotyped using the Affymetrix 6.0 GeneChip array.
CAG and CSGA samples comprise both children and adults with asthma (physician
diagnosis, symptoms, and airway responsiveness by methacholine challenge or
bronchodilator reversibility). Individuals in these studies were recruited from multiple
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locations, but only those recruited from clinics at the University of Chicago, University of
Maryland – Baltimore, and Wake Forest University and who had genome wide genotype
data were included in the current analysis. SARP included individuals with mild to severe
asthma.(31) Non-asthmatic control subjects were recruited from the same clinic sites for
these studies. The subjects were genotyped on the Illumina 1M version 1 BeadChip.
Meta-analysis for serum total IgE
Given the different platforms used to genotype the EVE cohorts, imputation was used to
create a common and near complete set of SNP genotypes across all groups. Each research
group used the program, MACH,(32) to impute genotypes in their respective study
population(s) using the reference panels from HapMap phase 2, release 21. For European
American individuals, haplotypes from the CEPH European Americans of Northern and
Western European ancestry (CEU) were used as the reference. For African American and
African Caribbean individuals, both the CEU and the Yoruba of West African (YRI)
haplotypes served as reference. For Latino individuals, the haplotypes from all of the
original HapMap population groups (i.e., CEU, YRI, Japanese from Tokyo [JPT], and the
ethnic Han Chinese from Beijing [CHB]) were used as reference. Poorly imputed SNPs with
MACH r-squared values <0.3 were removed from the analysis.
For analysis, study subjects were stratified by study cohort, race-ethnicity (i.e., African
Caribbean and African American combined, European American, and Latino), and asthma
status. The dependent variable, serum total IgE, was logarithmically (natural log)
transformed to normalize its distribution and diminish the effect of outliers; five individuals
with total IgE values <2 IU/ml were also excluded from the analysis. As has been done for
other genetic analyses,(33) we used Studentized residuals to standardize the distributions of
log-transformed IgE values across race-ethnic groups, asthma disease status, and study
populations. For each within study population group, we generated Studentized residuals
adjusted for age and sex, whereby the residuals represented the remaining variation in total
IgE after adjustment. Because these residuals were normally distributed, these steps ensured
a comparable scale for the regression coefficient summarizing the association between each
SNP and total IgE, thus limiting bias in the meta-analysis arising from distributional
differences in total IgE levels across groups. These residuals were then used as the primary
phenotype for association with the allele dosage estimates for each genotype. We assumed
an additive genetic model with the reference allele coded as zero. To account for underlying
population structure, study-specific genome wide principal components generated by the
program EIGENSOFT were included as covariates.(34) Given the extended pedigree
structure of GRAAD-AC, a linear mixed effects model using a kinship matrix approach was
employed for this cohort;(35) this method corrects for familial correlation (both known and
unknown) by estimating the empirical kinship between all pairs of subjects.
We used the analytic software, METAL,(36) to perform the meta-analysis. This program
used an inverse normal approach to combine stratum specific p-values, which accounted for
both the direction of effect and the sample size of each stratum. The meta-analysis was
performed for the overall sample and within the race-ethnic groups (i.e., African Caribbean
and African American individuals combined, European Americans, and Latinos). The most
significant SNP associations (P value <5.0 × 10−6) were promoted for replication if they
were informative in at least two of the three race-ethnic groups (i.e., a minor allele
frequency ≥5%). This threshold was similar to that suggested by others for genome-wide
association studies,(37) but was less stringent than the Bonferroni corrected value (P value
<5.0 × 10−8) which may overly conservative. We elected to use the former so as to provide a
feasible number of SNPs for assessing replication. When multiple SNPs in a region met this
criterion, we selected the polymorphism with the greatest overall statistical significance. We
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also assessed for heterogeneity of the top SNP associations by race-ethnicity and asthma
disease status using the Cochran’s Q-test as implemented in METAL.(36;38)
Replication populations and analysis
The top 10 signals were replicated in six case-control and population-based samples from
the U.S and Canada and a founder population in the U.S. The U.S. replication populations
included a separate group of individuals from SAPPHIRE,(39) the Gene-Environments and
Admixture in Latino Americans (GALA II) study, and the Study of African Americans,
Asthma, Genes & Environments (SAGE [U.S.]).(40) The Canadian cohorts included the
Canadian Asthma Primary Prevention Study (CAPPS)(41;42) and the Study of Asthma Genes
and the Environment (SAGE [Canada]).(42;43) The U.S. founder population consisted of
Hutterites who live in South Dakota.(44)
The SAPPHIRE study participants included in the replication were those without genome
wide association data who were age 12–56 years, had a physician diagnosis of asthma, and
no prior diagnosis of COPD or CHF. Replication controls were also age 12–56 years; had no
prior diagnosis of asthma, COPD, or CHF; and were recruited within the same health care
system.
The GALA II study is a large case-control study recruiting Latino patients with and without
asthma (physician diagnosed) from clinical sites in San Francisco, New York City, Houston,
Chicago, and Puerto Rico. Individuals were recruited at age 8–21 years. The SAGE (U.S.)
study was overseen by the same research team, and recruited African American individuals
with and without a physician diagnosis of asthma from the San Francisco Bay area. Case
patients were age 8–40 years and had physician diagnosed asthma. Control patients in both
GALA II and SAGE were enrolled from the same clinics concurrently and had no prior
diagnosis of allergies, asthma, lung disease, symptoms consistent with asthma within the
preceding 2 years, and <10 pack-year smoking history.
The Canadian SAGE study was a population-based birth cohort consisting of individuals
born in Manitoba in 1995. From this group, a nested case-control study was selected,
representing children with and without pediatrician diagnosed asthma. Serum total IgE was
measured between the ages of 7–10 years. CAPPS, another birth cohort, included infants
born between October 1994 and August 1996 who were deemed to be at high risk for
developing allergies as a result of ≥1 1st degree relative with asthma or ≥2 first degree
relatives with an IgE-mediated allergic disease.
The founder population comprised the Schmiedeleut Hutterites residing in primarily South
Dakota. This extended pedigree has been used in prior investigations of allergy and
asthma.(44–46)
Replication genotype data was generated from either allelic discrimination (TaqMan®,
Applied Biosystems, Foster City, California) or commercially available high-throughput
arrays. For the SAPPHIRE and SAGE cohorts all replication SNPs were genotyped by
allelic discrimination. In GALA II genome wide array results were available from the
Axiom LAT array (Affymetrix, Inc., Santa Clara, California) for rs9469220 and
rs16977747, and the remaining SNP were genotyped using TaqMan. In the two Canadian
cohorts, rs321588, rs7751374, rs10124954, and rs6499255 were genotyped on the Illumina
Human610-Quad array; rs9469220, rs537526, and rs16977747 were imputed using MACH;
rs2885872 was a genotyped proxy (CEU r2=1.0) used for rs2363709; and rs10043454 and
rs4355582 were imputed proxies used for rs13361473 and rs10944017, respectively.
Amongst the Hutterites, rs9469220, rs7751374, rs10124954, rs537526, and rs16977747
were genotyped on the Affymetrix 6.0 GeneChip, and rs613614, rs2101567, rs9314043, and
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rs11075734 were used as genotype proxies for rs321588, rs2363709, rs13361473, and
rs6499255, respectively.
We applied a similar analytic approach as used in the discovery cohorts to the assessment of
the replication data. Groups were stratified according to cohort, race-ethnicity, and asthma
status. Standardized residuals from the linear models associating natural log transformed
serum total IgE levels with age and sex were used in second stage models in association
with replication genotypes. The association with genotype was assessed assuming an
additive genetic model. We again used METAL(36) to combined stratum specific p-values.
Analyses were performed for the overall replication sample and within groups defined by
race-ethnicity (i.e., for European American, African American, and Latino individuals).
RESULTS
The characteristics of the six study groups in the genome wide meta-analysis of serum total
IgE levels are shown in Table 1 (individuals in GRAAD recruited from the U.S. and the
Caribbean are shown separately). These cohorts comprised 4,292 study subjects which
ranged in age from 1 to 84 years. The combined group included 2,425 (56.5%) females and
2,754 (64.1%) with a history of asthma. The race-ethnic breakdown of the total group
included 2,469 (57.4%) African American and African Caribbean individuals, 259 (6.0%)
Latino individuals, and 1,564 (36.4%) European American individuals. The distribution of
serum total IgE levels by race-ethnicity, asthma status, and study is shown in the online
supplement (eTable 1).
Association for total IgE was performed within groups stratified by race-ethnicity, asthma
status, and study cohort. Within the cohorts with a single population group represented (i.e.,
SAPPHIRE, GRAAD-AC, GRAAD-AA, GALA, and CAMP), we stratified by asthma
status alone. Association statistics were meta-analyzed accounting for the direction of the
effect and sample size. The overall association results and the associations within each race-
ethnic group are shown in Table 2 (parameter estimates for these associations are shown in
eTable 2 of the online supplement). The Manhattan plot for the genome wide meta-analysis
is shown in Figure 1 and the quantile-quantile plot is shown eFigure 1 of the online
supplement. Ten distinct regions were identified where the combined P-value was <5.0 ×
10−6 and the association was informative in ≥2 population groups. Most of the regions
associated with total IgE levels were novel with the exception of HLA-DQB1.
Six study populations consisting of 5,767 individuals were available to replicate the findings
of the discovery set (Table 3). The replication set comprised 2,961 (51.3%) African
American individuals, 1,477 (25.6%) Latino individuals, and 1,329 (23.0%) European
American individuals; 3,930 (68.1%) had a history of asthma. The association statistics for
replication set were combined in a manner analogous to the discovery set. As shown in
Table 4, of the ten SNPs analyzed for replication, only rs9469220 near HLA-DQB1 reached
marginal significance (P-value = 0.0074 [replication set]; P-value = 2.45 × 10−7 [combined
discovery and replication set]) (parameter estimates for these associations are shown in
eTable 3 of the online supplement). There was also some evidence for possible
heterogeneity at rs16977747 on chromosome 17 by population group and asthma status (i.e.,
strongest association for both Latino individuals and those with asthma – eTables 4 and 5 in
the online supplement).
We also assessed variants in genes described in earlier genome wide association studies of
serum total IgE levels (Table 5). We found that many of the genes (and variants) identified
in these earlier studies replicated in the current meta-analysis. Genes with evidence of
replication in all of our study groups combined included DARC, FCER1A, RAD50, IL13,
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HLA-DQA2, and STAT6. Not surprisingly, some of the variants showed differences in
statistical significance by population group, whereas others (e.g., rs2858331 in HLA-DQA2)
showed a consistent pattern in all population groups. Interestingly, the variant, rs2858331,
which has been ascribed to HLA-DQA2,(47) is located ~20 kilobases (kb) from our top hit,
rs9469220. Figure 2 shows the linkage disequilibrium (LD) between rs9469220 and
rs2858331 and the other SNPs in the HLA-DR/DQ region. eTable 6 in the supplement
shows the SNP association statistics for polymorphisms where we had data and which were
located within 20 kb of the transcription start and stop site for genes shown in Table 5.
DISCUSSION
We are aware of two genome wide association studies(4;47) and one genome wide meta-
analysis examining genetic variants associated with serum total IgE levels.(6) However, to
our knowledge this is the first of such studies to include substantial numbers of participants
who are not primarily European in ancestry (i.e., African American and Latino individuals).
Our findings confirm the role of variants in the class II major histocompatibility complex
(MHC) region on serum total IgE levels. In particular, we found that a polymorphism,
rs9469220, located between HLA-DQB1 and HLA-DQA2 was associated with total IgE
levels. The diversity of our study population further supported the importance of this locus
on IgE levels, as the relationship was consistent across multiple population groups and was
robust to differences in asthma-disease status.
Moffatt and colleagues as part of the GABRIEL (A Multidisciplinary Study to Identify the
Genetic and Environmental Causes of Asthma in the European Community) Consortium
also recently described markers around HLA-DRB1 and HLA-DQB1 to be associated with
total IgE levels, although the latter was more strongly associated with asthma.(6) A recent
GWAS of participants enrolled in the Framingham Study also found that a polymorphism
just upstream of HLA-DQA2 (rs2858331) was significantly associated with total IgE
levels.(47) Others testing more limited numbers of SNPs have found relationships between
polymorphisms in the HLA-DR/DQ region and IgE levels.(48;48;49) Therefore, our results
support the findings of these earlier studies and extend them to encompass most major North
American population groups.
Total IgE production is promoted through elaboration of type 2 helper T cell (Th2)
cytokines, such as interleukin (IL)-4 and IL-5.(50) Type 1 helper T cell (Th1) and Th2
activation may in turn depend on the number of MHC class II molecules involved in
presentation and the presence or absence of co-stimulation through CD28.(51) Curiously,
querying gene expression results from lymphoblastoid cell lines derived from HapMap
individuals,(52) we found that our most significant polymorphism in the HLA-DR/DQ
region, rs9469220, is related to the expression of a number of MHC class II molecules. This
same SNP has also been shown to be associated with Crohn’s disease,(53) which is
considered at least in part to be a Th1 condition.(54)
We found evidence for replication in genes previously identified in other genome wide
analyses and candidate gene studies as being associated with total IgE levels. As shown in
Table 5, these genes included DARC,(47;55) FCER1A,(4;6;47) RAD50,(4;49) IL13,(4;6;47;49;56)
HLA-DQA2,(47) STAT6,(4;6;47;57) and IL4R/IL21R.(6) Most importantly, we now
demonstrate that these relationships are present in multiple population groups.
We also identified at least 2 other loci (rs2363709 on Chromosome 3 and rs16977747 on
Chromosome 17) that were associated with serum total IgE levels with possible
heterogeneous associations across population groups and disease state. Further studies will
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be needed to assess whether these represent true ancestry-specific or asthma-specific (or
non-asthma specific) determinants of IgE levels.
This study was not without limitations. First, to remove the potential confounding influence
of race-ethnicity, asthma-status, and study cohort, we first stratified our analytic groups by
these categories and then recombined the resultant association statistics via meta-analysis.
Therefore, despite our large overall study size, the power within each population-specific
stratum was limited. Second, although we accounted for the important confounders such as
sex and age,(58) many other factors which can influence IgE levels were not available for
inclusion in our models, such as the season in which an IgE sample was drawn,(59;60) use of
systemic corticosteroids, and exposure to tobacco smoke.(11;61) While these missing factors
may have confounded our analysis, it is heartening to see that we could replicate many of
the previously described associations. In addition, we cannot say with certainty that the
variants we identified by association are causally related to IgE levels; rather, these
polymorphism may be in LD with the true causal variant. Because patterns of LD may vary
by race-ethnicity, it is also possible that the true causal variant still differs by population
group.(62) Determining these causal variants will likely require additional, finer scale
genotyping and follow-up functional studies.
In summary, our findings provide further evidence for a role of the HLA-DR/DQ region in
serum total IgE levels. Importantly, this study suggests that this region has similar
determinative import in European American, African American, and Latino individuals. Our
study also replicates many of the previously identified genetic associations with total IgE in
these three population groups. Preliminary evidence for genetic predictors which vary by
race-ethnicity and asthma status will need to be replicated in the respective population
groups. Nevertheless, this study underscores the need to study diverse populations so as to
identify both shared and group-specific genetic predictors.
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Figure 1.
Manhattan plot of the genome wide association results for serum total IgE from the meta-
analysis. The significance level used to promote single nucleotide polymorphisms for
replication (P < 5.0 × 10−6) is denoted by the dashed line. The solid line shows the genome
wide significance level of P < 5.0 × 10−8.
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Figure 2.
Locus zoom plots of rs9469220 (triangle) located between HLA-DQB1 and HLA-DQA2 on
chromosome 6 and its association with serum total IgE levels. The plots show the
association P-values (derived from the genome wide meta-analysis) and the linkage
disequilibrium (with rs9469220) in color for the surrounding single nucleotide
polymorphisms in European American individuals (A), African American individuals (B),
and Latino individuals (C). The polymorphism near HLA-DQA2, rs2858331, identified by
Granada et al.(47) is also shown (square).
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Ra
ce
-e
th
ni
ci
ty
 (S
AP
PH
IR
E)
, th
e G
en
eti
c R
ese
arc
h o
n A
sth
ma
 in
 th
e A
fri
ca
n D
ias
po
ra-
Af
ric
an
 C
ari
bb
ea
n (
GR
AA
D-
AC
)
st
ud
y,
 th
e 
G
en
et
ic
 R
es
ea
rc
h 
on
 A
sth
m
a 
in
 th
e 
A
fri
ca
n 
D
ia
sp
or
a-
A
fri
ca
n 
A
m
er
ic
an
 (G
RA
AD
-A
A)
 st
ud
y, 
the
 G
en
eti
cs 
of 
As
thm
a i
n L
ati
no
 A
me
ric
an
s (
GA
LA
) s
tud
y; 
the
 C
hil
dh
oo
d A
sth
ma
 M
an
ag
em
en
t
Pr
og
ra
m
 (C
AM
P)
, th
e C
hil
dh
oo
d A
sth
ma
 R
ese
arc
h a
nd
 E
du
ca
tio
n N
etw
ork
 (C
AR
E)
; th
e C
hic
ag
o A
sth
ma
 G
en
eti
cs 
(C
AG
) s
tud
y, 
the
 N
ati
on
al 
He
art
, L
un
g, 
an
d B
loo
d I
ns
titu
te 
Co
lla
bo
rat
ive
 St
ud
ies
 of
 th
e
G
en
et
ic
s o
f A
sth
m
a 
(C
SG
A)
, a
nd
 th
e S
ev
ere
 A
sth
ma
 R
ese
arc
h P
rog
ram
 (S
AR
P)
. A
sso
cia
tio
ns
 w
ere
 fi
rst
 as
ses
sed
 in
 gr
ou
ps
 st
rat
ifi
ed
 by
 ra
ce
-et
hn
ici
ty,
 as
thm
a s
tat
us
, a
nd
 st
ud
y b
efo
re 
me
ta-
an
aly
tic
all
y
co
m
bi
ni
ng
 to
 g
en
er
at
e 
th
e 
ov
er
al
l a
nd
 p
op
ul
at
io
n 
gr
ou
p 
re
su
lts
.
† T
he
 fi
rs
t a
lle
le
 c
or
re
sp
on
ds
 to
 th
e 
“r
ef
er
en
ce
/o
th
er
” 
al
le
le
 in
 d
bS
N
P 
bu
ild
 1
25
.
‡ T
he
 ri
sk
 a
lle
le
 d
en
ot
es
 th
e 
al
le
le
 a
ss
oc
ia
te
d 
w
ith
 h
ig
h 
se
ru
m
 to
ta
l I
gE
 le
ve
ls 
fo
r a
ll 
gr
ou
ps
 c
om
bi
ne
d.
§ Id
en
tif
ie
d 
by
 W
ei
di
ng
er
 e
t a
l.(4
)
‖ Id
en
tif
ie
d 
by
 M
of
fa
tt 
et
 a
l.(6
)
¶ Id
en
tif
ie
d 
by
 G
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na
da
 e
t a
l.(4
7)
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N
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 im
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